MRC Laboratory of Molecular Biology

2023 World Laureates Association Prize winners awarded in Shanghai

Retrieved on: 
星期二, 十一月 7, 2023
Computer science, WLA, United Kingdom, MRC Laboratory of Molecular Biology, Science, Mathematics, History, Research, University of Colorado Boulder, Molecular biology, University, Pharmaceutical industry, Video game, ETH Zurich, Medicine

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- The five winners of the 2023 World Laureates Association Prize (WLA Prize) received their awards for their ground-breaking achievements in computer science or mathematics and life science or medicine on Nov. 6 at the opening ceremony of the 6th WLA Forum held in China's financial hub Shanghai, the forum's permanent site.

Key Points: 
  • SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- The five winners of the 2023 World Laureates Association Prize (WLA Prize) received their awards for their ground-breaking achievements in computer science or mathematics and life science or medicine on Nov. 6 at the opening ceremony of the 6th WLA Forum held in China's financial hub Shanghai, the forum's permanent site.
  • Initiated by the World Laureates Association, the WLA Prize is an annual international science prize established in Shanghai in 2021 and exclusively funded by venture capital and private equity firm HongShan.
  • They won the WLA Prize in Computer Science or Mathematics "for their seminal work in convex optimization theory."
  • Both the inaugural WLA Prize laureates and the new winners attended the forum, participating in a series of events like the WLA Prize Laureates Lecture and the WLA Prize Laureates Roundtable, engaging in meaningful conversations with other scientists and sharing insightful inspirations with the scholars across the globe.

2023 World Laureates Association Prize winners awarded in Shanghai

Retrieved on: 
星期二, 十一月 7, 2023
Computer science, WLA, United Kingdom, MRC Laboratory of Molecular Biology, Science, Mathematics, History, Research, Multimedia, University of Colorado Boulder, Molecular biology, University, Film industry, Pharmaceutical industry, Video game, ETH Zurich, Medicine

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- The five winners of the 2023 World Laureates Association Prize (WLA Prize) received their awards for their ground-breaking achievements in computer science or mathematics and life science or medicine on Nov. 6 at the opening ceremony of the 6th WLA Forum held in China's financial hub Shanghai, the forum's permanent site.

Key Points: 
  • SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- The five winners of the 2023 World Laureates Association Prize (WLA Prize) received their awards for their ground-breaking achievements in computer science or mathematics and life science or medicine on Nov. 6 at the opening ceremony of the 6th WLA Forum held in China's financial hub Shanghai, the forum's permanent site.
  • Initiated by the World Laureates Association, the WLA Prize is an annual international science prize established in Shanghai in 2021 and exclusively funded by venture capital and private equity firm HongShan.
  • Both the inaugural WLA Prize laureates and the new winners attended the forum, participating in a series of events like the WLA Prize Laureates Lecture and the WLA Prize Laureates Roundtable, engaging in meaningful conversations with other scientists and sharing insightful inspirations with the scholars across the globe.
  • Caption: Five WLA Prize Laureates received medals at the 2023 WLA Prize Award Ceremony of the 6th World Laureates Forum on November 6.

The 2023 WLA Prize Award Ceremony to be Held in Shanghai on Nov. 6

Retrieved on: 
星期三, 十一月 1, 2023
System, Science, WLA, RMB, MRC Laboratory of Molecular Biology, 2019 Cricket World Cup opening ceremony, H. Milton Stewart School of Industrial and Systems Engineering, ETH, Biochemistry, Life, Operation, Emeritus, Professor, Crystallography, Chromatin, International Journal of Biological Macromolecules, Georgia Tech, University of Colorado Boulder, Mathematics, Georgia Institute of Technology School of Physics, Medicine, Ceremony, Molecular biology, University, Computer science, Video game, Pharmaceutical industry

The World Laureates Association Prize (WLA Prize) is an international science prize established in Shanghai, in 2021, initiated by the World Laureates Association (WLA),  managed by the WLA Foundation, and exclusively funded by HongShan.

Key Points: 
  • The World Laureates Association Prize (WLA Prize) is an international science prize established in Shanghai, in 2021, initiated by the World Laureates Association (WLA),  managed by the WLA Foundation, and exclusively funded by HongShan.
  • Each year, the WLA Prize is awarded in two categories: "Computer Science or Mathematics" and "Life Science or Medicine", with the total award for each Prize being RMB 10 million.
  • The 2023 WLA Prize in Computer Science or Mathematics recognizes two scientists: Arkadi Nemirovski, the John P. Hunter, Jr.
  • Continuing last year's tradition, the ceremony will be held at the Opening Ceremony of the 6th WLA Forum, an annual scientific event which also features WLA Prize related academic lectures and dialogues starting from Nov. 5.

The 6th WLA Forum Will Embark on New Journey in Shanghai

Retrieved on: 
星期一, 十月 30, 2023
Carbon, Mobius, Destiny, System, Forum, WLA, Education, MRC Laboratory of Molecular Biology, H. Milton Stewart School of Industrial and Systems Engineering, Biochemistry, Turing Award, Operation, ETH, Emeritus, Community of Common Destiny, Professor, Crystallography, Golden Joystick Awards, International Journal of Biological Macromolecules, Research, Multilateralism, Georgia Tech, University of Colorado Boulder, Biology, Student, Europe-Georgia Institute, Molecular biology, University, Nobel Prize, Physics, Wolf Prize, World Cultural Council 30th Award Ceremony, ARD International Music Competition, Video game, Whaling, Management, Science, Chemistry

The Award Ceremony of the 2023 WLA Prize will be held on November 6 at the opening ceremony of the 6th WLA Forum.

Key Points: 
  • The Award Ceremony of the 2023 WLA Prize will be held on November 6 at the opening ceremony of the 6th WLA Forum.
  • Under the annual theme "Science Leads Transformation," the 6th WLA Forum introduces several notable enhancements to its dynamic program – a new chairmanship to the WLA featured forums, such as the WLA Life Science Forum, WLA Intelligent Science Forum, WLA Zero Carbon Forum, WLA Young Scientists Forum, etc.
  • Additionally, a new academic lecture series, the WLA Frontier Lectures, featuring approximately 60 scholarly presentations that showcase cutting-edge research progress will be launched at the 6th WLA Forum.
  • The five laureates of the 2023 WLA Prize announced last month will attend the 6th WLA Forum in person.

Laureates of the 2023 WLA Prize Announced

Retrieved on: 
星期四, 九月 14, 2023
DNA, Operation, Mathematics, DNA condensation, Georgia Tech, Emeritus, System, H. Milton Stewart School of Industrial and Systems Engineering, Crystallography, ETH, Prize, Chromatin, MRC Laboratory of Molecular Biology, WLA, Georgia Institute of Technology School of Computer Science, Research, International Journal of Biological Macromolecules, History, RMB, DNA replication, Machine learning, Algorithm, Engineering, Nucleosome, Computer science, Economics, Pharmaceutical industry, Management, Medical imaging, Microscope, Nesterov, Chemistry, Medicine, Physiology

Shanghai, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The World Laureates Association Prize (WLA Prize) unveils its 2023 laureates on Thursday, at a press conference held in Shanghai.

Key Points: 
  • Shanghai, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The World Laureates Association Prize (WLA Prize) unveils its 2023 laureates on Thursday, at a press conference held in Shanghai.
  • The 2023 WLA Prize in Computer Science or Mathematics recognizes two scientists: Arkadi Nemirovski, John P. Hunter, Jr.
  • The 2023 WLA Prize Award Ceremony is scheduled to take place in Shanghai on November 6, followed by a series of engaging sessions to celebrate the laureates' outstanding achievements.
  • The WLA Prize is an international science prize established in Shanghai, in 2021, initiated by the World Laureates Association (WLA), managed by the WLA Foundation, and exclusively funded by HongShan.

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Retrieved on: 
星期三, 九月 6, 2023
Anantara New York Palace Budapest Hotel, Pancreatic cancer, Patent, Masonic Cancer Center, University, University of Minnesota, United States Patent and Trademark Office, Clinical trial, Cancer, Ageing, Gynecologic Oncology (journal), Research, Inflammation, Cell, MRC Laboratory of Molecular Biology, EDT, Trial of the century, Drug resistance, Molecular biology, National Cancer Institute, Professor, Patient, Division, Colorectal cancer, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Immune system, Gynaecology, UMN, Principal, Lotte New York Palace Hotel, NCI, Notifiable disease, Immunosuppression, Natural killer T cell, Laboratory, Conference, Pharmaceutical industry, Vaccine, Obstetrics

On September 12, 2023, the Company will be meeting individual investors in person at the conference venue, the Lotte New York Palace Hotel in New York.

Key Points: 
  • On September 12, 2023, the Company will be meeting individual investors in person at the conference venue, the Lotte New York Palace Hotel in New York.
  • In addition, a pre-recorded, virtual Company update will be available on demand beginning at 7:00 a.m. EDT on September 11, 2023 for all who register for the conference.
  • Due to clinical protocol requirements, dosing of the remaining patients is expected to take place in the next 3 to 6 months.
  • Dr. Geller stated, “Our team is very excited to bring this clinical trial to patients who have recurrent cancer.

Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute

Retrieved on: 
星期二, 三月 14, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Laboratory, Breast, ARTEMIS, MRC Laboratory of Molecular Biology, National Cancer Institute, MSLN, Molecular biology, Therapy, Safety, Mesothelioma, NCI, Canadian Aviation Regulations, Cancer, Bangladesh Technical Education Board, Vaccine

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka’s proprietary ARTEMIS® T-cell receptor platform.

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T-cell therapies to treat cancer, today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to develop and commercialize a novel antibody targeting mesothelin (MSLN) in combination with Eureka’s proprietary ARTEMIS® T-cell receptor platform.
  • MSLN is a cell-surface protein overexpressed in many solid tumors, including mesothelioma, ovarian, pancreatic, breast and lung cancers, making it a promising target for cancer therapies.
  • The NCI antibody licensed to Eureka has shown potential in preclinical studies to selectively bind to and kill cancer cells expressing MSLN while sparing normal cells, which could make it an effective cancer treatment.
  • By combining the newly licensed MSLN-targeting antibody with the ARTEMIS T-cell receptor platform, Eureka and NCI intend to develop a next-generation T-cell therapy that can effectively target and eliminate MSLN-expressing cancer cells.

HCW Biologics Enters CRADA with National Cancer Institute

Retrieved on: 
星期四, 十二月 8, 2022
Laboratory, Molecular biology, MRC Laboratory of Molecular Biology, CCR, Adenocarcinoma, Pancreatic cancer, Degenerative disease, Inflammation, Bifunctional, Safety, CRADA, University of Minnesota, Cancer, Tissue, ClinicalTrials.gov, Cooperative research and development agreement, Masonic Cancer Center, Principal, Recurrence, Adenosquamous carcinoma, National Cancer Institute, Diabetes, Neurodegeneration, Internal medicine, Oncology, Survival, Research, NCI, IND, Disease, HCW, Death, University, Development, Patient, Drug resistance, Incidence, Pharmaceutical industry, Dietary supplement

MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.

Key Points: 
  • MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.
  • About the Center for Cancer Research at the National Cancer Institute:
    The Center for Cancer Research (CCR), NCI’s specialized internal cancer center, has a robust clinical research program, the largest at the National Institutes of Health.
  • Pancreatic cancer is the third leading cause of cancer death in the United States.
  • The invention of HCW Biologics’ two lead molecules, HCW9218 and HCW9302, was made via the TOBI™ discovery platform.

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate

Retrieved on: 
星期一, 十一月 7, 2022
Drug, MRC Laboratory of Molecular Biology, Laboratory, Neoplasm, NCI, National, Physician, Cooperative research and development agreement, Molecular biology, Cancer, Non-small-cell lung carcinoma, Engineering, Development, CRADA, HIO, Patient, Triple-negative breast cancer, Program, Pharmaceutical industry, Vaccine, Thorax

PHILADELPHIA, Nov. 7, 2022 /PRNewswire/ --Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.

Key Points: 
  • PHILADELPHIA, Nov. 7, 2022 /PRNewswire/ --Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.
  • Under this CRADA, Navrogen will sponsor the clinical investigation of the experimental antibody-drug conjugate, NAV-001, under the supervision of Dr. Raffit Hassan, Chief of Thoracic and GI Malignancies Branch at the NCI.
  • "NAV-001 has proven to be very effective with single, sub-mg/kg dosing against various patient-derived tumor types in mouse models, causing significant regression of the cancer lesions."
  • Navrogen is a biotechnology company focused on the discovery of tumor-produced Humoral Immuno-Oncology (HIO) factors that are associated with suppressed humoral immunity, poor prognosis and limited therapeutic response of immune-mediated anti-cancer therapies.

Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma

Retrieved on: 
星期二, 十月 18, 2022
Research, Public Policy, Government, Clinical Trials, Biotechnology, White House, Federal Government, Health, Pharmaceutical, Science, Oncology, Disease, Therapy, Laboratory, Antibody, Patient, Neuroblastoma, MRC Laboratory of Molecular Biology, ARTEMIS, Cancer, Lymphatic system, National Cancer Institute, Squamous cell carcinoma, National, GPC2, Toxicity, Adult, Pediatrics, Medulloblastoma, NCI, Molecular biology, Nervous system, Pharmaceutical industry, San Francisco Bay Area

The therapy also has expansion potential in medulloblastoma and small cell lung cancer, among several other pediatric and adult cancers that express an abundance of the GPC2 protein on their cell surface.

Key Points: 
  • The therapy also has expansion potential in medulloblastoma and small cell lung cancer, among several other pediatric and adult cancers that express an abundance of the GPC2 protein on their cell surface.
  • Neuroblastoma is a rare cancer that affects the development of the nervous system by attacking immature nerve cells as early as the embryonic stage.
  • Each year, about 800 children are diagnosed with neuroblastoma in the U.S., and overall survival rates are lower than 50%.
  • Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers.